Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SANTA CLARA, Calif., Sept. 27, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, today announces the appointment of Laurie Heilmann as Chief Business Officer. Since 2014, Heilmann has served as Crown Bioscience’s Sr. Vice President; Global Strategy, Business Development, Marketing.
“Laurie is the ideal leader for our strategic commercial operations, possessing a diverse therapeutic background and over three decades of experience aligning sales and marketing with R&D to steer company strategy,” said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. “As Sr. Vice President; Global Strategy, Business Development, Marketing, Laurie led Crown Bioscience through three years of sustained, exponential growth and guided expansion of our innovative scientific technology platform. I am excited to continue working closely with Laurie to provide our clients with the insight and understanding they need to advance their preclinical research projects.”
“I am honored to be assuming the role of Chief Business Officer at Crown Bioscience,” said Laurie Heilmann, former Sr. Vice President; Global Strategy, Business Development, Marketing.at Crown Bioscience. “I look forward to continuing to work with Dr. Wery and our talented, dedicated team of scientists, business development and marketing professionals building our translational technology platform to help our clients address global health challenges.”
Laurie is an active member of numerous industry organizations, and holds a bachelor’s degree in science and business administration. She possesses a therapeutic and life science technology background which includes cardiovascular, oncology, immunology and metabolic disease and over three decades of global experience aligning sales and marketing with R&D to steer company strategy. As Chief Business Officer, Laurie will be responsible for world-wide sales, strategy and marketing at Crown Bioscience.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc. [email protected]
